SingulaBio

The latest news in cell therapeutics.
Visit for more.

[SingulaBio @BioSingula]

At Singula Bio, we are delighted to be sharing you this recent interview between one of our founders, @ProfAhmedA and none other than leading global biotech company, @miltenyibiotec .
Clink the link below to read the full interview with Prof Ahmed!
https://t.co/1JPoB5RlWr

[Nuffield Dept of Women's & Reproductive Health @Ox_wrh]

Here is a great video created by @OxfordAhmedLab to explain the role of the fallopian tubes in serous ovarian cancer. You can also read more about our findings on the fallopian tubes at single cell level here: https://t.co/MOZRzbH4v5 @zhi_yuan_hu https://t.co/KrN8lvLeIJ 3/3

[SingulaBio @BioSingula]

Not even the rain could dampen their spirits!

Congratulations to @ProfAhmedA, Joel Nulsen and
Lili Wang from the Singula Bio team for taking part in the Oxford Town and Gown run last Sunday to raise money for Muscular Dystrophy UK .
Well done, team!

[SingulaBio @BioSingula]

We are delighted to announce that one of our founders, @ProfAhmedA , received a front cover publication in The Journal of Clinical Investigation's JCI insight for his paper on minimal residual disease (MRD).

Click the link to read!
https://t.co/evDmSEq1Cs

[SingulaBio @BioSingula]

Singula Bio is #hiring !
We're looking for a full time Senior Scientist in Translational Cancer Immunology to join our growing, international team of translational researchers and immunologists.

Clink the link below for more details and to apply!
https://t.co/qMmPDiKTnu

[SingulaBio @BioSingula]

Singula Bio is #hiring !
We're looking for a full time senior scientist in cancer genomics to join our growing, international team of translational researchers and immunologists.

Clink the link below to find out more and to apply!
https://t.co/VHs4H9vt7P

[University of Oxford @UniofOxford]

.@BioSingula's patient-centred approach will pioneer immunological, medical, surgical and computational technologies to generate selective therapies that eliminate cancer.

Learn more: https://t.co/S0qOMm7EK9

#WorldHealthDay

[SingulaBio @BioSingula]

We are delighted to welcome our new, Non Executive Director, Dr James Hall. James is currently CEO of Betagenon AB, a Swedish clinical stage biotech. He has also held several senior roles at AstraZeneca and previously worked in the Pharma/Biotech practice at McKinsey & Co.

[SingulaBio @BioSingula]

Part 2 of our interview with Profs @ProfAhmedA and Enda McVeigh. Have a read below to see what sets us apart and how we envisage the future of cancer treatment.

[Medical Sciences @OxfordMedSci]

NEWS: @BioSingula, a bold new seed-stage biotechnology @UniofOxford spinout, launched this week. Led by @Ox_wrh cancer specialists it aims to become a world leader in therapies to use against difficult-to-treat solid malignancies, such as ovarian cancer.

https://t.co/p3Z9x4loNk

[SingulaBio @BioSingula]

At Singula Bio, we want to give you the opportunity to get to know us a bit better.
We got our founders, Profs Enda McVeigh and @ProfAhmedA , together for an interview to giving you a greater insight into how we started and what we aim to achieve. Stay tuned tomorrow for part 2!

[Nuffield Dept of Women's & Reproductive Health @Ox_wrh]

Cancer Need not be Fatal - This is the core mission of
@BioSingula - a bold new Oxford spinout launching today! It will draw on a multi-discipline approach for therapies which work with a patient to eliminate cancer.

Read more https://t.co/eNPqGSfoEy

@ProfAhmedA @OxfordMedsci

[SingulaBio @BioSingula]

Our press release is live!
Follow the link below to read about our ground-breaking, innovative work in the field of cancer treatment.

https://t.co/SLA368EFwi

[SingulaBio @BioSingula]

What does joining Singula Bio mean to you?
Joel Nulsen, our new Computational Biology scientist, tells us, "The team pulls together a wealth of experience from across industry, academia and the clinic, and we hope to measure our success in real improvements to patients’ lives."

[SingulaBio @BioSingula]

Breaking down the science! Our immune system reacts to mutations in cancer cells by generating “T cells” to attack them. These T cells can become exhausted and so at Singula Bio, we aim to identify them, expand them outside the body and deliver them back to fight the tumour.